This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Paul D. Thompson, MD; Anne M. Nugent, RN; Peter N. Herbert, MD
The Miriam Hospital Brown University Providence, RI

JAMA. 1990;264(23):2992.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Creatine kinase (CK) elevations of at least twice normal occurred in 11% of patients during clinical trials of lovastatin (J. H. Milander, MD, personal communication, 1989), and rhabdomyolysis with renal failure has occurred with lovastatin in combination with other medications.¹ Physical exertion can also injure muscle. Average CK levels over 3000 U/L have been noted in runners after a 42-km marathon.²

We recently participated in a study using fluvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, lovastatin, and placebo. Twenty-three men and 13 women received placebo for 6 weeks followed by 6 weeks of placebo or fluvastatin. Thirty-four patients subsequently received lovastatin. Four men receiving reductase inhibitors developed elevated CK levels after exercise, suggesting that these drugs exacerbate the muscle injury associated with exertion (Table).

Patient 1 (Table) began jogging and weight lifting several days before phlebotomy. Patient 2 played squash for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?